GlassScriptPhysician profile
Mallorie Emory
NPI 1396484952
$3,421.86
in general payments reported to CMS, 2019-2025
45 companies · $1,705 in 2025
The $1,705 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $281 · 2024: $1,437 · 2025: $1,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,065 · Education: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,065.06 |
| Education | $356.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $599.20 | 2023-2025 | Enhertu, Vanflyta, Datroway |
| Pfizer INC. | $280.49 | 2023-2025 | |
| Janssen Biotech, INC. | $268.19 | 2024-2025 | Darzalex, Talvey, Rybrevant |
| Abbvie INC. | $221.94 | 2024-2025 | |
| Seagen INC. | $175.17 | 2023-2025 | Adcetris |
| Novartis Pharmaceuticals Corporation | $144.58 | 2024-2025 | |
| Lilly USA, LLC | $122.24 | 2024-2025 | Verzenio, Jaypirca |
| Genentech USA, INC. | $116.25 | 2023-2025 | Phesgo, Tecentriq, Polivy |
| Merck Sharp & Dohme LLC | $111.79 | 2024-2025 | Keytruda, Welireg |
| Astrazeneca Pharmaceuticals LP | $109.02 | 2023-2025 | Enhertu |
| Pharmaessentia USA Corporation | $108.05 | 2024-2025 | Besremi |
| Incyte Corporation | $103.50 | 2023-2025 | Jakafi, Niktimvo, Zynyz |
| Tersera Therapeutics LLC | $97.21 | 2023-2025 | Zoladex, Xermelo |
| Eisai INC. | $85.82 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $83.29 | 2023-2024 | Mychoice Cdx, Endopredict |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $62.96 | 2024-2025 | |
| Geron Corporation | $54.94 | 2025 | Rytelo |
| Karyopharm Therapeutics INC. | $42.03 | 2023-2024 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $40.66 | 2025 | Alunbrig, Hyqvia |
| Sobi, INC | $39.40 | 2025 | |
| Tempus Ai, INC | $39.20 | 2025 | Xt Cdx |
| Alexion Pharmaceuticals, INC. | $36.26 | 2024-2025 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $33.90 | 2023-2024 | Tavalisse, Rezlidhia |
| Array Biopharma INC | $30.07 | 2024 | Mektovi, Braftovi, Lorbrena |
| E.R. Squibb & Sons, L.L.C. | $30.06 | 2024 | Opdivo, Opdualag |
| Puma Biotechnology, INC. | $28.83 | 2024-2025 | |
| Octapharma USA, INC. | $26.13 | 2024 | Octagam Immune Globulin (Human) |
| Emd Serono, INC. | $25.16 | 2024 | |
| Stemline Therapeutics INC. | $24.38 | 2025 | Orserdu |
| Azurity Pharmaceuticals, INC. | $22.02 | 2025 | Danziten |
| Exelixis INC. | $21.20 | 2024 | Cabometyx |
| Servier Pharmaceuticals LLC | $21.13 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $20.66 | 2024 | Somatuline Depot, Onivyde |
| Immunogen, INC. | $20.30 | 2023 | Elahere |
| Deciphera Pharmaceuticals INC. | $19.82 | 2025 | Romvimza, Qinlock |
| Beone Medicines USA, INC. | $19.51 | 2025 | Brukinsa |
| Caris Mpi, INC. | $16.65 | 2025 | Mi Cancer Seek |
| Recordati_rare_diseases_inc. | $15.98 | 2025 | Enjaymo |
| Kyowa Kirin, INC. | $15.44 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.26 | 2025 | |
| Springworks Therapeutics, INC. | $15.21 | 2025 | Ogsiveo |
| Adc Therapeutics America, INC. | $15.11 | 2025 | |
| Beigene USA, INC. | $14.93 | 2025 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $14.05 | 2025 | Libtayo |
| Pharmacosmos Therapeutics INC. | $13.87 | 2024 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallorie Emory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.